Thera-SAbDab

ANIFROLUMAB

>   Structural Summary
TherapeuticAnifrolumab
TargetIFNAR1
Heavy ChainEVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS
Light ChainEIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCQQYDSSAITFGQGTRLEIK
100% seqID Fv Structure4qxg [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental TechnologyMedarex UltiMAb Mouse
INN Year Proposed2013
INN Year Recommended2014
Companies InvolvedMedarex, Medical University of Vienna, MedImmune
Conditions Approvedna
Conditions ActiveSystemic lupus erythematosus, Lupus nephritis, Rheumatoid arthritis
Conditions DiscontinuedScleroderma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]